Last reviewed · How we verify

Fentanyl and bupivacaine

Hospital Central Dr. Luis Ortega · FDA-approved active Small molecule

Fentanyl is a potent opioid agonist that binds mu opioid receptors to provide analgesia, while bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve signal transmission.

Fentanyl is a potent opioid agonist that binds mu opioid receptors to provide analgesia, while bupivacaine is a local anesthetic that blocks sodium channels to prevent nerve signal transmission. Used for Regional anesthesia and analgesia, Perioperative pain management, Local infiltration anesthesia with systemic analgesia.

At a glance

Generic nameFentanyl and bupivacaine
SponsorHospital Central Dr. Luis Ortega
Drug classOpioid analgesic combined with local anesthetic
TargetMu opioid receptor (fentanyl); voltage-gated sodium channels (bupivacaine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

This is a combination product where fentanyl acts systemically as an opioid analgesic for pain relief, and bupivacaine acts locally at the site of administration by blocking voltage-gated sodium channels in nerve fibers, preventing action potential propagation. Together they provide both systemic and local anesthesia/analgesia, commonly used in regional anesthesia and pain management procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: